(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 17.55% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.76%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Transmedics Group's revenue in 2026 is $635,890,000.On average, 15 Wall Street analysts forecast TMDX's revenue for 2026 to be $26,009,850,400, with the lowest TMDX revenue forecast at $24,074,093,775, and the highest TMDX revenue forecast at $27,169,714,574. On average, 15 Wall Street analysts forecast TMDX's revenue for 2027 to be $30,893,998,343, with the lowest TMDX revenue forecast at $28,793,731,781, and the highest TMDX revenue forecast at $33,385,840,026.
In 2028, TMDX is forecast to generate $35,666,860,152 in revenue, with the lowest revenue forecast at $32,226,321,462 and the highest revenue forecast at $40,159,778,582.